Linda S. Steelman - Concepedia

Author

Linda S. Steelman

East Carolina University

Also Known As

L S Steelman, L Steelman, L. Steelman, LS Steelman, Linda S Steelman, Linda S. Steelman, Linda Steelman

150

Publications

16.2K

Citations

H-Index

Concepts

All Affiliations

East Carolina University University of Bologna University of Catania University of Palermo National Research Council

About

Linda S. Steelman is an author at East Carolina University specializing in medicine, cell biology, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	27	43	3.4K
2	Cell Biology	25	34	2.9K
3	Health Sciences	9	9	1K
4	Cellular Physiology	1	1	25
5	Endocrinology	1	1	17

Linda S. Steelman

Publications

4.1K

Citations

H-Index

Page 1

	Year	Citations
Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance James A. McCubrey, Linda S. Steelman, Steven L. Abrams, Advances in Enzyme Regulation Tumor BiologyHealth SciencesPi3k/pten/akt PathwaysMedicineReceptor Tyrosine Kinase	2006	658
Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway (Review). Fumin Chang, Linda S. Steelman, John G. Shelton, PubMed ApoptosisCell DeathCell CycleCancer BiologyCell Death Mechanisms	2003	393
EGFR family signaling and its association with breast cancer development and resistance to chemotherapy (Review) Patrick M. Navolanic, Linda S. Steelman, James A. McCubrey International Journal of Oncology Epidermal Growth FactorBreast OncologyDownstream Signaling PathwaysCell DeathCancer Biology	2003	175
Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors Linda S. Steelman, Patrick M. Navolanic, Melissa L. Sokolosky, Oncogene Breast OncologyPten Function IncreasesMedicineBreast CancerPharmacotherapy	2008	171
Phosphatidylinositol 3′-Kinase Activation Leads to Multidrug Resistance Protein-1 Expression and Subsequent Chemoresistance in Advanced Prostate Cancer Cells John Tayu Lee, Linda S. Steelman, James A. McCubrey Cancer Research	2004	157
The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy Stephen L. Abrams, Linda S. Steelman, John G. Shelton, Cell Cycle Drug Resistant CellsChemoprevention StrategyApoptosisCell DeathRaf/mek/erk Pathway	2010	136
Raf-1 and Bcl-2 induce distinct and common pathways that contribute to breast cancer drug resistance. Julianne M. Davis, Patrick M. Navolanic, Caroline Weinstein‐Oppenheimer, PubMed Breast OncologyCancer BiologyTumor BiologyDrug ResistanceDoxorubicin Resistance	2003	117
Roles of signaling pathways in drug resistance, cancer initiating cells and cancer progression and metastasis James A. McCubrey, Stephen L. Abrams, Timothy L. Fitzgerald, Advances in Biological Regulation Cancer ResearchHealth SciencesMolecular PathwayMedicineCancer Progression	2014	112
p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3 William H. Chappell, Brian D. Lehmann, David M. Terrian, Cell Cycle P53 Transcription FactorP53 Expression ControlsUrologyOncologyMedicine	2012	110
Synergy between PI3K/Akt and Raf/MEK/ERK Pathways in IGF-1R Mediated Cell Cycle Progression and Prevention of Apoptosis in Hematopoietic Cells John G. Shelton, Linda S. Steelman, Edmond R. White, Cell Cycle ApoptosisImmunologyCell DeathIgf-1r-mediated Signal TransductionCell Cycle	2004	108

Page 1